Aardvark Therapeutics AARD
NASDAQ AARD
$1.37 +0.02 (+1.48%)
As of: Nov 10, 2026 · 3:59 PM EST

Aardvark Therapeutics (AARD) EBIT (2024 - 2026)

Updated

Aardvark Therapeutics (AARD) reported EBIT of -$15.08 million for Q2 2026, compared with -$15.85 million a year earlier.

Analysis

Aardvark Therapeutics (AARD) EBIT (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Aardvark Therapeutics' EBIT came in at -$73.96 million; for FY2025, it came in at -$62.73 million.

  • By year, EBIT came in at -$22.79 million in FY2024.
  • The Q2 2026 figure ranks as the highest quarterly EBIT since Q1 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -$22.46 million (Q1 2026), -$18.7 million (Q4 2025) and -$17.7 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 12.79 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 6.18 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 6.27 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 5.59 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 3.16 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 3.71 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 3.46 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 5.47 Bn
10 Aardvark Therapeutics 30.58 Mn -43.32 Mn - -15.08 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.08 Mn
Mar 31, 2026 -22.46 Mn
Dec 31, 2025 -18.70 Mn
Sep 30, 2025 -17.70 Mn
Jun 30, 2025 -15.85 Mn
Mar 31, 2025 -10.47 Mn
Dec 31, 2024 -9.45 Mn
Sep 30, 2024 -5.09 Mn
Jun 30, 2024 -6.07 Mn
Mar 31, 2024 -2.17 Mn
API Access

Aardvark Therapeutics EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=AARD&period=max&api_key=YOUR_API_KEY